{
    "id": 16858,
    "fullName": "RICTOR amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "RICTOR amplification indicates an increased number of copies of the RICTOR gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 253260,
        "geneSymbol": "RICTOR",
        "terms": [
            "RICTOR",
            "AVO3",
            "hAVO3",
            "PIA"
        ]
    },
    "variant": "amp",
    "createDate": "01/19/2016",
    "updateDate": "01/19/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4065,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma, harboring amplification of RICTOR, demonstrated stable disease when treated with Sapanisertib (MLN0128) (PMID: 26370156).",
            "molecularProfile": {
                "id": 17138,
                "profileName": "RICTOR amp"
            },
            "therapy": {
                "id": 1282,
                "therapyName": "Sapanisertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4051,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) resulted in increased phosphorylation of Akt and demonstrated a minimal effect on cell viability in non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification in culture, therefore resulting in no benefit (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4055,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 treatment did not affect cell viability in non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification in culture and therefore, provides no benefit (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4049,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification were sensitive to Vistusertib (AZD2014) in culture, resulting in decreased phosphorylation of downstream signaling targets and reduced cell viability (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4058,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 treatment did not affect cell viability in non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification in culture and therefore, provides no benefit (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4048,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells co-harboring a KRAS mutation and RICTOR amplification were sensitive to BEZ235 in culture, resulting in decreased phosphorylation of downstream signaling targets and reduced cell viability (PMID: 26370156).",
            "molecularProfile": {
                "id": 17139,
                "profileName": "KRAS mut RICTOR amp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4888,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 treatment inhibited mTOR signaling and cell viability in lung cancer cell lines harboring RICTOR amplification and PDGFRA amplification in culture (PMID: 26370156)",
            "molecularProfile": {
                "id": 19448,
                "profileName": "PDGFRA amp RICTOR amp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4890,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) treatment inhibited mTORC1 signaling and cell viability in lung cancer cell lines harboring RICTOR amplification and PDGFRA amplification in culture (PMID: 26370156)",
            "molecularProfile": {
                "id": 19448,
                "profileName": "PDGFRA amp RICTOR amp"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4889,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) treatment inhibited mTOR signaling and cell viability in lung cancer cell lines harboring RICTOR amplification and PDGFRA amplification in culture (PMID: 26370156).",
            "molecularProfile": {
                "id": 19448,
                "profileName": "PDGFRA amp RICTOR amp"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4386,
                    "pubMedId": 26370156,
                    "title": "RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26370156"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17138,
            "profileName": "RICTOR amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7626,
                    "name": "mTOR Inhibitor",
                    "profileName": "RICTOR amp"
                }
            ]
        },
        {
            "id": 17139,
            "profileName": "KRAS mut RICTOR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19448,
            "profileName": "PDGFRA amp RICTOR amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}